Biocartis Group NV

Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
  • TickerBCART
  • ISINBE0974281132
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium
Alan Vandenberghe ...
  • Michiel Declercq
  • Thomas Vranken
  • Wido Jongman
  • Wim Hoste

Morning Note: BCART BB, COLR BB, DECB BB, DIE BB, QRF BB

Biocartis: Expanding EGFR testing alongside AstraZeneca Colruyt: Acquisition of Belgian fitness chain (JIMS) D'Ieteren: April car registrations jump 602.3% to 37.2k Deceuninck: Frank Deceuninck raises stake above 5% threshold Qrf: 1Q21 trading update as expected

Dylan Van Haaften

BIOCARTIS (BUY, TP EUR8) | Expansion for Idylla AZ collab marks real progress in CDx model :

BIOCARTIS (BUY, TP EUR8) | Expansion for Idylla AZ collab marks real progress in CDx model :

Alan Vandenberghe ...
  • Bart Cuypers
  • Ruben Devos
  • Thomas Couvreur
  • Thomas Vranken
  • Wido Jongman
  • Wim Hoste

Morning Note: AED BB, AKZA NA, AVTX NA, BFIT NA, BCART BB, EURN BB, FUR NA, INTER EN, REL LN, SIP BB, SLIGR NA, TNET BB, UMI BB

Aedifica: New note published: Outgrowing “das Heimatland” Akzo Nobel: How to spend it – new company note Avantium: Agreement with Cosun on plant-based glycols JV Basic-Fit: Imminent club re-opening saves the day Biocartis: Q1: Re-accelerating to new heights Euronav: New gen VLCC orders Fugro: EBIT improvement y/y despite topline hit Intertrust: 1Q21 in line with expectations RELX Group: 1Q21: Good start, but Exhibitions remains an issue Sipef: Good volumes and positive profit guidance revision Sligro: Soft 1Q due to lockdown but 2Q recovery expected Telenet: Introduction of new product line-up...

Alan Vandenberghe ...
  • Michiel Declercq
  • Thomas Vranken
  • Wido Jongman
  • Wim Hoste

Morning Note: BCART BB, COLR BB, DECB BB, DIE BB, QRF BB

Biocartis: Expanding EGFR testing alongside AstraZeneca Colruyt: Acquisition of Belgian fitness chain (JIMS) D'Ieteren: April car registrations jump 602.3% to 37.2k Deceuninck: Frank Deceuninck raises stake above 5% threshold Qrf: 1Q21 trading update as expected

Dylan Van Haaften

BIOCARTIS (BUY, TP EUR8) | Expansion for Idylla AZ collab marks real progress in CDx model :

BIOCARTIS (BUY, TP EUR8) | Expansion for Idylla AZ collab marks real progress in CDx model :

Alan Vandenberghe ...
  • Bart Cuypers
  • Ruben Devos
  • Thomas Couvreur
  • Thomas Vranken
  • Wido Jongman
  • Wim Hoste

Morning Note: AED BB, AKZA NA, AVTX NA, BFIT NA, BCART BB, EURN BB, FUR NA, INTER EN, REL LN, SIP BB, SLIGR NA, TNET BB, UMI BB

Aedifica: New note published: Outgrowing “das Heimatland” Akzo Nobel: How to spend it – new company note Avantium: Agreement with Cosun on plant-based glycols JV Basic-Fit: Imminent club re-opening saves the day Biocartis: Q1: Re-accelerating to new heights Euronav: New gen VLCC orders Fugro: EBIT improvement y/y despite topline hit Intertrust: 1Q21 in line with expectations RELX Group: 1Q21: Good start, but Exhibitions remains an issue Sipef: Good volumes and positive profit guidance revision Sligro: Soft 1Q due to lockdown but 2Q recovery expected Telenet: Introduction of new product line-up...

Dylan Van Haaften

BIOCARTIS (BUY, TP EUR8) | MSI test submission for FDA 510(k):

BIOCARTIS (BUY, TP EUR8) | MSI test submission for FDA 510(k)

Bart Cuypers ...
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste

Morning Note: AKZA NA, ARCAD NA, BCART BB, FLOW NA, HEIA NA

Akzo Nobel: Preview 1Q21: adj. operating profit estimate +25% Arcadis: Steady as she goes Biocartis: 510(k) submission of MSI Test Flow Traders: 1Q21 results: again beating CSS-high Heineken: Preview: 1Q beer volume estimate -3.1%

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 27 September 2019

On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The sole agenda item relates to the proposed approval and ratification, in accordance with Article 556 of the Belgian Companies Code, of conditions of the convertible bonds in case of a change of control. These are standard provisions and they are in line with the market practice. Hence, we see no reason for shareholder concern and recommend to approve.

Expert Corporate Governance Service (ECGS)

Biocartis - AGM 10 May 2019

In general, BIOCARTIS is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting.  Under ITEM 6, the board of directors seeks approval of the Company's remuneration report. Although amounts at stake are very moderate compared to sector and market practice, ECGS has concerns over the poor disclosure of the company and the lack of LTI component. Thus ECGS recommends to vote OPPOSE.

An unfavourable environment weighs on BIOCARTIS GROUP, which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of BIOCARTIS GROUP (BE), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date February 16, 2021, the closing price was EUR 4.62 and its target price was estimated at EUR 3.10.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch